于报告期内，该集团创新发展迈入新里程：随着莱芙兰(亚甲蓝肠溶缓释片)于报告期内中国获批上市，处于商业化阶段的创新药组合已扩充至五款产品。在“以患者为中心”理念指引下，该集团围绕医学证据驱动学术推广，全力建设创新产品品牌力，加速渠道拓面与市场渗透。新采纳与“新产品上市”和“新产品销售”相关的股份激励计划，不断激励员工持续为新产品上市和销售做出卓越贡献。Announcements on August 16, $CMS (00867.HK)$ The 2024 interim results were announced, with turnover of approximately RMB 3.611 billion, up 6.1%; gross profit of 2.6965 billion yuan, up 7.7% month-on-month; R&D expenses of about 0.106 billion yuan, up 39.39% year on year; profit for the period was about 0.903 billion yuan, up 92.8% month-on-month; basic profit per share was 0.3734 yuan, and an interim dividend of 0.1507 yuan per share.
In the first half of 2024, the group's Yousifer and Boyiding continued to implement the eighth batch of national volume procurement (national procurement), which had a negative impact on business performance; all three domestically procured products (Dailixin, Yousifer, and Boeidine) decreased 1.1969 billion yuan compared to the same period last year in terms of drug sales revenue, a year-on-year decrease of 49.2%. However, the group's overall turnover and profit for the period showed a month-on-month growth trend compared to the second half of last year, indicating that the negative impact of China Procurement on the Group has basically been digested and has entered a “new product era” where performance growth is driven by exclusive products and innovative products from non-national procurement.
In the first half of 2024, the total revenue of the group's exclusive and innovative products based on pharmaceutical sales was RMB 24,047 billion, accounting for 56.1% of the total sales revenue calculated based on pharmaceutical sales revenue. The group will continue to promote more differentiated and innovative products into the commercialization stage every year in the future, laying the foundation for sustainable, high-quality rapid development.
During the reporting period, the group's innovative development reached a new milestone: as Levland (methylene blue enteric extended-release tablets) was approved for listing in China during the reporting period, the innovative drug portfolio in the commercialization stage was expanded to five products. Guided by the “patient-centered” concept, the group focuses on medical evidence to drive academic promotion, make every effort to build innovative product brands, and accelerate channel expansion and market penetration. A new share incentive plan related to “new product launches” and “new product sales” has been adopted to continuously motivate employees to continue to make outstanding contributions to the launch and sale of new products.
At the same time, the Group promotes the standardization and digital development of all nodes of the product system and commercialization system, strengthens the connection efficiency and management capabilities of innovative products throughout the life cycle, supports the Group to continuously export more new drugs and good drugs with higher efficiency and more controllable costs, and accelerate innovative therapies to benefit patients.
